Breast milk

Novel Research Illuminates Breast Milk's Unique Contribution to COVID-19 Defense in Infants

Retrieved on: 
Tuesday, March 5, 2024

LISBON, Portugal, March 5, 2024 /PRNewswire/ -- The International Conference on Human Milk Science and Innovation (ICHMSI) has announced that Dr. Yarden Golan Maor is the fifth recipient of the Ruth A. Lawrence Investigator Award for Research in Human Milk Science.

Key Points: 
  • Dr. Golan's research, titled " Milk antibody response after 3rd COVID-19 vaccine and SARS-CoV-2 infection and implications for infant protection ," analyzed antibodies in breast milk following vaccination and breakthrough infection.
  • Infant saliva also contained more abundant immunoglobulin A (IgA) from breast milk than immunoglobulin G (IgG), and IgA persisted longer post-feeding.
  • Her research highlights antibody transfer to infants through breastfeeding, strengthening the understanding of breast milk's role against infectious diseases.
  • She has over 10 years of experience in molecular biology and nutrition, and her research focuses on human milk science.

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

Dr. Jose Villar Wins 2024 March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition

Retrieved on: 
Tuesday, February 20, 2024

ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition. Dr. Villar, a Professor of Perinatal Medicine at Oxford's Nuffield Department of Women's and Reproductive Health and the former Coordinator of Maternal and Perinatal Health at the World Health Organization (WHO) has spent more than a half century researching the effect of maternal nutrition on the health, growth, and development of babies. The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.

Key Points: 
  • Prominent Oxford scientist led studies on fetal growth, newborn size, and preterm postnatal growth
    ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition.
  • The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.
  • They present a universal blueprint for healthy growth and development from early gestation to two years of age.
  • That is the challenge ahead, and I couldn't be prouder to continue it alongside March of Dimes."

InventHelp Inventor Develops Bra with a Built-In Breast Pump (JKK-175)

Retrieved on: 
Tuesday, February 13, 2024

The invention provides a more comfortable and convenient method of pumping breast milk.

Key Points: 
  • The invention provides a more comfortable and convenient method of pumping breast milk.
  • In doing so, it eliminates the need to sit while holding a breast pump or bottles.
  • The invention features a comfortable and user-friendly design that is easy to wear and use so it is ideal for nursing mothers.
  • 22-JKK-175, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Retrieved on: 
Friday, February 2, 2024

DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Please see important safety information below. Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.

Key Points: 
  • We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50 million annual Nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • Nitisinone Capsules are available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
  • Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals.
  • To report a suspected adverse event related to Nitisinone, contact Eton Pharmaceuticals, Inc. at: 1-855-224-0233 or the US Food and Drug Administration at www.fda.gov/medwatch or call 1-800-FDA-1088.

Kabrita Brings the First and Only European and Goat Milk-Based Infant Formula to Meet All FDA Requirements to the U.S.

Retrieved on: 
Tuesday, January 9, 2024

BOSTON, Jan. 9, 2024 /PRNewswire/ -- Kabrita, the leading global goat milk formula manufacturer, has introduced the first and only goat milk-based infant formula to meet all FDA requirements in the United States. This comes following years of clinical testing, proving Kabrita's infant formula is safe and that it can provide complete nutrition for a baby's growth in the first year. Kabrita can maintain consistent product production, giving parents peace of mind the infant formula is here for their baby's entire feeding journey.

Key Points: 
  • Produced with European Standards in the Netherlands, Kabrita's formula is backed by 75 years of trusted infant formula experience
    BOSTON, Jan. 9, 2024 /PRNewswire/ -- Kabrita , the leading global goat milk formula manufacturer, has introduced the first and only goat milk-based infant formula to meet all FDA requirements in the United States.
  • Kabrita can maintain consistent product production, giving parents peace of mind the infant formula is here for their baby's entire feeding journey.
  • With over 75 years of formula experience, Kabrita is the #1 goat milk formula worldwide, feeding 1.5 million babies daily.
  • Kabrita Goat Milk-Based Infant Formula is now available for purchase on Kabrita.com (two-pack for $89.99) and Amazon (suggested MSRP of $46.99).

Momcozy's Guide to a Cozy Christmas Eve: Perfect for New Moms Looking to Celebrate in Comfort

Retrieved on: 
Tuesday, December 19, 2023

This Christmas Eve, let Momcozy products be a trusted companion, ensuring both moms and little ones experience the utmost comfort and peaceful sleep for a Cozy Holiday.

Key Points: 
  • This Christmas Eve, let Momcozy products be a trusted companion, ensuring both moms and little ones experience the utmost comfort and peaceful sleep for a Cozy Holiday.
  • The comforting white noise produced by the magical machine creates a womb-like environment that helps babies fall asleep faster and deeper.
  • Moms can also experience unmatched comfort all day long this Christmas  with the HF006 CozyFitClasp Pumping Bra .
  • Its snug, true-to-size fit ensures a perfect fit, while adjustable straps allow moms to customize their comfort.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.

Key Points: 
  • “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Mycotopia Therapies Acquires AI Robotics Assets with a Total Transaction Value of $9 Million

Retrieved on: 
Monday, December 4, 2023

MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (“Mycotopia Therapies”) (“the Company”) (OTC: TPIA) announced today it has purchased certain assets of Philon Labs, LLC ("Philon Labs"), including patents related to innovative AI robotics based home health products.

Key Points: 
  • MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (“Mycotopia Therapies”) (“the Company”) (OTC: TPIA) announced today it has purchased certain assets of Philon Labs, LLC ("Philon Labs"), including patents related to innovative AI robotics based home health products.
  • With this acquisition Mycotopia Therapies has begun its transition to a growth-oriented company using Artificial Intelligence ("AI") to transform great ideas and innovative solutions into disruptive products using advanced engineering and design techniques.
  • Phill is the first massage robot with a 35 inch range, 15 lb massage force and is AI controlled.
  • The Milkyway app offers real-time updates on freezing temperature and milk inventory, aiding in monitoring the baby's breastfeeding habits and schedules.